Overview

A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine whether locally advanced breast cancer responds (by shrinking, by not progressing or by being destroyed) to combined chemotherapy (gemcitabine, epirubicin and paclitaxel) given before surgery to patients with locally advanced breast cancer. This study will also evaluate the toxicity of the chemotherapy combination to patients and will determine survival and progression-free survival 2 years after treatment. Also, the study will look at whether there are molecular and genetic changes in the tumor tissue that match the tumor's response to the chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

NSABP Foundation Inc

Treatments:

Albumin-Bound Paclitaxel
Epirubicin
Gemcitabine
Paclitaxel